Biogen Inc. (BIIB) was upgraded to a "buy" by TheStreet's Quant Ratings service on Wednesday. This biotech name has made a chart that could be challenging to many traders and investors. Let's drill down and see if an easier approach to the long side can be found.
More from Stocks
These well-known names are displaying both technical and quantitative deterioration.
Selling requires you to be honest with yourself, which may be the biggest challenge in trading and investing.
Market participants like to believe they aren't gamblers but there's no denying that luck plays a major role in the investment process.
This market simply has no fear of staying with the big-cap tech names that have been leaders for so long.